Search results
Purdue Pharma and its subsidiaries develop, manufacture and market medications to meet the evolving needs of healthcare professionals, patients and caregivers. Purdue’s plan of reorganization will deliver billions in value to communities across the country to fund programs specifically for abatement of the opioid crisis.
Sep 1, 2021 · Purdue Pharma, the maker of the highly addictive painkiller OxyContin, was dissolved on Wednesday in a wide-ranging bankruptcy settlement that will require the company’s owners, members of the...
Dec 4, 2023 · Dec. 4, 2023. The Supreme Court heard arguments on Monday over a bankruptcy deal for Purdue Pharma that would give billions of dollars to those harmed by the opioid epidemic in exchange for...
Dec 7, 2023 · Purdue Pharma’s bankruptcy agreement was reached after years of lawsuits against the company and its owners over their alleged role in the skyrocketing number of opioid addictions since...
Upon emergence, Purdue Pharma will cease to exist and substantially all of Purdue’s assets will be transferred to a new company called Knoa Pharma, with a uniquely public-minded mission. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners, customers, and consumers. About Knoa Pharma.
Aug 11, 2023 · Aug. 11, 2023. The Supreme Court announced on Thursday that it would pause a bankruptcy deal for Purdue Pharma that would give billions of dollars to those harmed by the opioid epidemic in...
Purdue Pharma Headquarters. Purdue Pharma L.P. Adlon Therapeutics L.P. Imbrium Therapeutics L.P. Greenfield BioVentures L.P. One Stamford Forum. 201 Tresser Boulevard. Stamford, CT 06901-3431. Main Phone: 203‑588‑8000. Medical Inquiries/Drug Safety: 888‑726‑7535. Customer Service: 800‑877‑5666. Main Fax: 203‑588‑8850. Driving Directions. + −.
